Intermittent versus continuous erlotinib with concomitant modified "xELOX" (q3W) in first-line treatment of metastatic colorectal cancer: Correlation with Serum Amphiregulin and Transforming Growth Factor Alpha

Cancer

Volumn 119, Issue 23, 2013, Pages 4145-4153

  Ma, Brigette B Y ^a   Chan, Stephen L ^a   Ho, Wing M ^a   Lau, Wilson ^a   Mo, Frankie ^a   Hui, Edwin P ^a   Chan, Charles ^a   Poon, Annette ^a   Dattatray, Rasalkar D ^a   Wong, S C Cesar ^b   To, Ka F ^a   King, Ann D ^a   Ahuja, Anil ^a   Chan, Anthony T C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

amphiregulin; capecitabine; erlotinib; oxaliplatin; transforming growth factor alpha

Indexed keywords

AMPHIREGULIN; CAPECITABINE; ERLOTINIB; OXALIPLATIN; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEUTROPENIA; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AMPHIREGULIN; CAPECITABINE; ERLOTINIB; OXALIPLATIN; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PATIENT COMPLIANCE; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RAS PROTEINS; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 84888006783     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28327     Document Type: Article

References (36)

1. Tournigand C, Scheithauer W, Lledo G, et al. Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial. J Clin Oncol. 2012; 30 (suppl): abstract LBA3500.
2. Weickhardt AJ, Price TJ, Chong G, et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol. 2012; 30: 1505-1512.
3. Ouchi KF, Yanagisawa M, Sekiguchi F, Tanaka Y,. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol. 2006; 57: 693-702.
4. Azzariti A, Xu JM, Porcelli L, Paradiso A,. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839). Biochem Pharmacol. 2004; 68: 135-144.
5. Xu JM, Severino M, Lu B, Colucci G, Paradiso A,. Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. Biochem Pharmacol. 2003; 66: 551-563.
6. Solit DB, She Y, Lobo J, et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res. 2005; 11: 1983-1989.
7. Chau I, Cunningham D, Hickish T, et al. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. Ann Oncol. 2007; 18: 730-737.
8. Hartmann JT, Pintoffl JP, Kroning H, et al. Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO). Onkologie. 2008; 31: 237-241.
9. Kuo T, Cho CD, Halsey J, et al. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol. 2005; 23: 5613-5619.
10. Messersmith WA, Jimeno A, Jacene H, et al. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer. 2011; 9: 297-304.
11. Meyerhardt JA, Clark JW, Supko JG, et al. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2007; 60: 661-670.
12. Meyerhardt JA, Zhu AX, Enzinger PC, et al. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol. 2006; 24: 1892-1897.
13. Van Cutsem E, Verslype C, Beale P, et al. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Ann Oncol. 2008; 19: 332-339.
14. Nagahara H, Mimori K, Ohta M, et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res. 2005; 11: 1368-1371.
15. Ogino S, Meyerhardt JA, Cantor M, et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005; 11: 6650-6656.
16. Addison CL, Ding K, Zhao H, et al. Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. J Clin Oncol. 2010; 28: 5247-5256.
17. Ishikawa N, Daigo Y, Takano A, et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res. 2005; 65: 9176-9184.
18. Masago K, Fujita S, Hatachi Y, et al. Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer. Cancer Sci. 2008; 99: 2295-2301.
19. Mutsaers AJ, Francia G, Man S, et al. Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. Clin Cancer Res. 2009; 15: 2397-2405.
20. Morelli MP, Cascone T, Troiani T, et al. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol. 2005; 16 (suppl 4): 61-68.
21. Simon R, Wittes RE, Ellenberg SS,. Randomized phase II clinical trials. Cancer Treat Rep. 1985; 69: 1375-1381.
22. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008; 26: 2006-2012.
23. Cassidy J, Twelves C, Brunet R, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004; 22: 2084-2091.
24. Santoro A, Comandone A, Rimassa L, et al. A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Ann Oncol. 2008; 19: 1888-1893.
25. Messersmith WA, Senzer NN, Donehower RC, et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res. 2004; 10: 6522-6527.
26. Moroni M, Sartore-Bianchi A, Benvenuti S, et al. Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. Ann Oncol. 2005; 16: 1848-1849.
27. Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2009; 27: 5068-5074.
28. Vollebergh MA, Kappers I, Klomp HM, et al. Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010; 5: 1939-1948.
29. Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Lloret R, Colomer R,. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (review). Int J Mol Med. 2007; 20: 3-10.
30. Shim KS, Kim KH, Park BW, et al. Increased serum levels of transforming growth factor-alpha in patients with colorectal cancer. Dis Colon Rectum. 1998; 41: 219-224.
31. Rothenberg ML, LaFleur B, Levy DE, et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol. 2005; 23: 9265-9274.
32. Mundle SD, Marathe AS, Chelladurai M,. Transient therapy-related surge in serum tumor biomarkers: Characterizing behavior and postulating its biologic role. Crit Rev Oncol Hematol. 2013; 86: 15-22.
33. Strimpakos AS, Cunningham D, Mikropoulos C, Petkar I, Barbachano Y, Chau I,. The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. Ann Oncol. 2010; 21: 1013-1019.
34. Tsai HL, Chang YT, Chu KS, et al. Carcinoembryonic antigen in monitoring of response to cetuximab plus FOLFIRI or FOLFOX-4 in patients with metastatic colorectal cancer. Int J Biol Markers. 2008; 23: 244-248.
35. Fisher GA, Kuo T, Ramsey M, et al. A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Clin Cancer Res. 2008; 14: 7074-7079.
36. Gelibter AJ, Gamucci T, Pollera CF, et al. A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. Curr Med Res Opin. 2007; 23: 2117-2123.